In mice, 400 mg γ-T3/kg, applied orally, sensitized pancreatic tumors to gemcitabine treatment, a drug applied in clinical treatment of pancreatic cancer, by suppressing NF-κB-mediated inflammatory pathways linked to tumorigenesis (Kunnumakkara et al., 2010). Here, NFKB1 is linked to familial pancreatic carcinoma.